Related Experiment Video
Updated: Dec 27, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A
Pramod Kumar Julka1, Amit Verma1, Kush Gupta2
1Max Institute of Cancer Care, New Delhi, India.
Abstract:
DNA repair mutations (BRCA1 and BRCA2) are found in metastatic castration-resistant prostate cancer (CRPC) patients. Here, we report a case of a 71-year-old male patient with metastatic CRPC along with BRCA2 and PTEN mutations. As per the genomic findings of the Foundation One report, FDA-approved therapies were available for other tumor types, such as olaparib for the loss of BRCA2 and everolimus for the loss of PTEN exons 2-9. These findings were confirmed in another novel phenotypic assay that revealed the sensitivity of olaparib and carboplatin combination therapy. After 4 cycles, our patient achieved a partial response along with a good performance status.
Insights
Metastatic castration-resistant prostate cancer (CRPC) with BRCA2 and PTEN mutations responded to targeted therapy. Olaparib and carboplatin combination showed efficacy in a patient with advanced prostate cancer.
Area of Science:
- Oncology
- Genetics
- Genomic Medicine
Background:
- Metastatic castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer.
- DNA repair gene mutations, including BRCA1 and BRCA2, are observed in CRPC patients.
- Identifying specific mutations can guide treatment strategies.
Observation:
- A 71-year-old male patient presented with metastatic CRPC.
- Genomic analysis revealed concurrent BRCA2 and PTEN mutations.
- A phenotypic assay confirmed sensitivity to olaparib and carboplatin.
Findings:
- The patient received olaparib for BRCA2 loss and everolimus for PTEN loss, based on FDA-approved indications for other tumor types.
- Combination therapy with olaparib and carboplatin demonstrated efficacy.
- After four cycles of treatment, the patient achieved a partial response and maintained a good performance status.
Implications:
- Targeted therapies, such as PARP inhibitors (e.g., olaparib), show promise for CRPC patients with DNA repair mutations.
- Combination therapies may enhance treatment outcomes in advanced prostate cancer.
- Genomic profiling is crucial for personalized treatment selection in CRPC.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers